Brain scans may guide depression treatment in new stanford trial
NCT ID NCT07022405
First seen May 17, 2026 · Last updated Jun 20, 2026 · Updated 4 times
Summary
This Stanford study tests whether the drug pramipexole can help people with depression, and whether brain scans can predict who will respond best. Sixty adults with current depressive symptoms will take pramipexole for 8 weeks, then taper off. The goal is to move toward personalized depression care by linking brain circuit function to treatment outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94305, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pramipexole immediate release
What this could lead to
If successful, this could point toward a more personalized treatment for depression by matching patients to medications based on their brain circuit activity.
What could go wrong
This is a small, early-phase study (60 people) with no placebo group, so results may not apply broadly. Pramipexole can cause side effects like nausea, dizziness, and impulse control issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.